Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Gene therapy maker bluebird bio said on Tuesday it plans to revise its financial statements for 2022 and the first three quarters of last year due to accounting errors related to some contract manufacturing agreements. https://t.co/oJWWdRsXCw https://t.co/oJWWdRsXCw
Bluebird's Lyfgenia launch gains traction but shares tumble with report of accounting errors https://t.co/EsZhOBHuko
Gene therapy maker bluebird bio said on Tuesday it plans to revise its financial statements for 2022 and the first three quarters of last year due to accounting errors related to some contract manufacturing agreements. https://t.co/mrA6LPs4Yw https://t.co/mrA6LPs4Yw
Gene therapy maker Bluebird Bio announced plans to restate its financial statements for 2022 and the first three quarters of 2022 and 2023 due to accounting errors related to contract manufacturing agreements. The company's Lyfgenia launch has seen progress, but its shares dropped following the report.
